Cargando…
A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease that lack of effective therapeutic drugs. K-001 is an oral antitumor drug made from active ingredients of marine microorganisms. The current study aimed to evaluate safety and antitumor activity of K-001 in patients with advance...
Autores principales: | Cui, Jiujie, Yang, Haiyan, Liu, Jue, Chen, Donghui, Hu, Jiong, Zhang, Haiyan, Wang, Yu, Han, Ting, Mao, Tiebo, Jiao, Feng, Biskup, Ewelina, Pan, Yaotian, Liu, Min, Wang, Liwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183060/ https://www.ncbi.nlm.nih.gov/pubmed/34098895 http://dx.doi.org/10.1186/s12885-021-08375-6 |
Ejemplares similares
-
A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
por: Wang, Yi, et al.
Publicado: (2018) -
A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated advanced pancreatic cancer
por: Yao, Jiayu, et al.
Publicado: (2021) -
Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response
por: Wang, Yu, et al.
Publicado: (2021) -
CSE1L, as a novel prognostic marker, promotes pancreatic cancer proliferation by regulating the AKT/mTOR signaling pathway
por: Zhang, Xiao, et al.
Publicado: (2021) -
Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma
por: Xue, Shengbai, et al.
Publicado: (2022)